Hui C. Liu

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Paul E. Sax, Edwin DeJesus, Anthony Mills et al. · The Lancet · 2012 · 443 citations

Hiv/aids Counselling, Medicine, Initial Treatment +10

Effect of Cobicistat on Glomerular Filtration Rate in Subjects With Normal and Impaired Renal Function

Polina German, Hui C. Liu, Javier Szwarcberg et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2012 · 164 citations

A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection

Andrew Zolopa, Paul E. Sax, Edwin DeJesus et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2013 · 145 citations

Serum Creatinine, Week 96, Treatment And Prevention +14

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy

Anthony Mills, Gordon Crofoot, Cheryl McDonald et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2015 · 139 citations

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

Calvin Cohen, Richard Elion, Peter Ruane et al. · AIDS · 2011 · 109 citations